Crossmark

Circulating tumor cell quantification during abiraterone plus prednisone therapy may estimate survival in metastatic castration-resistant prostate cancer patients

Crossref DOI link: https://doi.org/10.1007/s11255-023-03481-9

Published Online: 2023-01-29

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Gu, Tengfei

Li, Jie

Chen, Ting

Zhu, Qingfeng

Ding, Jiafeng https://orcid.org/0000-0003-4930-2969
License Information

Text and Data Mining valid from 2023-01-29

Version of Record valid from 2023-01-29
More Information

Article History

Received: 9 November 2022

Accepted: 21 January 2023

First Online: 29 January 2023

Declarations

:

: The authors have no conflicts of interest to declare.

: The study was approved by the Ethics Committee. Informed consent was obtained from each mCRPC patient.

Document is current

Any future updates will be listed below